Target
oriented
drug
Development
Pipeline
Development Status
Potential First-in-Class
& Best-in-Class NASH Drug
ㆍSubstantial potential market opportunity
ㆍDifferentiated mechanism of action
ㆍStrong efficacy data of FGF21 including:
ㆍThe levels of hepatic triglycerides and lipids
ㆍThe degree of vacuolization of liver
ㆍValidated Immunogenicity
Patented FGF21 design
& Manufacturing method
ㆍFive point-mutations for high affinity toward
β-Klotho and enhanced receptor activation
ㆍThe ever-first findings of
ㆍThe temperature-responsive structural
reversibility of FGF21 and
ㆍHeating-based purification of active FGF21
ㆍThese findings can be applied to FGF21 analogs that are under therapeutic development
Experienced & Validated Team in
the protein research field
Sun-shin Cha (professor at Ewha WomanUniversity) leads a competitive protein research groupThree LO experiences for β-lactamase inhibitors, human DJ-1 (park7), and FGF21 (to TODD) in KoreaAbout 133 publications including Nature, Immunity, Nature Genetics, Nature Chemical Biology, Nature Communications, EMBO J, PNAS, Angewandte Chemie, Nucleic Acid Research, JBC, etc.
News & Media
TODD is a “drug development company” that designs and develops protein-based and synthetic chemical pharmaceuticals based on innovative core technologies and business areas.
Our main business areas include the design of protein-based and synthetic chemical pharmaceuticals based on tertiary structures, the development of protein therapeutics for the treatment of metabolic diseases (such as obesity and diabetes), and the development of treatments for infections caused by multi-drug resistant bacteria.
We possess a variety of technologies and capabilities, including the development of protein therapeutics for the treatment of obesity and non-alcoholic steatohepatitis (NASH) (such as FGF21). Notably, we have technological excellence in protein drug purification methods using thermostability, as well as in the discovery and optimization of inhibitors against β-lactamase, an enzyme derived from multi-drug resistant pathogens.
Our main products and services include halisulfate, which exhibits β-lactamase inhibitory activity similar to avibactam already in clinical use, and an FGF21 variant (TODD-B-001), a candidate for the treatment of obesity and non-alcoholic steatohepatitis (NASH) in humans and pets, with 5.27 times the activity compared to the wild type. Additionally, we provide various services, such as structure-based protein and target-specific compound design services, recombinant production and purification services, and sales of recombinant proteins.